Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (31-40 of 247) with videos related to

Pageof 25
Sort By:
JCO Precision Oncology|January 7, 2022
Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint InhibitorsDaniel Schlauch, Xiaotong Fu, Suzanne F Jones, et al.
Journal of Pharmaceutical Sciences|June 2, 2011
Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumorsJean-Francois Marier, Leng Pheng, My My Trinh, et al.
Clinical Pharmacokinetics|April 5, 2013
An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancerDan Lu, Amita Joshi, Bei Wang, et al.
Clinical Breast Cancer|August 8, 2009
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancerDenise A Yardley, Howard A Burris, Sarah Hanson, et al.
Clinical Advances in Hematology & Oncology : H&O|August 17, 2012
A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancerJohanna C Bendell, Anthony Meluch, James Peyton, et al.
Journal of Clinical Pharmacology|June 9, 2015
Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancerEric Laille, Manish Patel, Suzanne F Jones, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2012
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumorsSuzanne F Jones, Jeffrey R Infante, Dana S Thompson, et al.
Clinical Breast Cancer|June 14, 2011
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research ConsortiumDenise A Yardley, Howard A Burris, Bobby L Clark, et al.
Clinical Lung Cancer|July 16, 2008
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancerSuzanne Jones, Dana Thompson, John Barton, et al.
Cancer Investigation|May 15, 2003
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Howard A Burris, Joan B Erland, et al.
Pageof 25

Showing results (31-40 of 247) with videos related to

Sort By:
Pageof 25
JCO Precision Oncology|January 7, 2022
Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint InhibitorsDaniel Schlauch, Xiaotong Fu, Suzanne F Jones, et al.
Journal of Pharmaceutical Sciences|June 2, 2011
Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumorsJean-Francois Marier, Leng Pheng, My My Trinh, et al.
Clinical Pharmacokinetics|April 5, 2013
An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancerDan Lu, Amita Joshi, Bei Wang, et al.
Clinical Breast Cancer|August 8, 2009
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancerDenise A Yardley, Howard A Burris, Sarah Hanson, et al.
Clinical Advances in Hematology & Oncology : H&O|August 17, 2012
A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancerJohanna C Bendell, Anthony Meluch, James Peyton, et al.
Journal of Clinical Pharmacology|June 9, 2015
Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancerEric Laille, Manish Patel, Suzanne F Jones, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2012
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumorsSuzanne F Jones, Jeffrey R Infante, Dana S Thompson, et al.
Clinical Breast Cancer|June 14, 2011
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research ConsortiumDenise A Yardley, Howard A Burris, Bobby L Clark, et al.
Clinical Lung Cancer|July 16, 2008
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancerSuzanne Jones, Dana Thompson, John Barton, et al.
Cancer Investigation|May 15, 2003
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Howard A Burris, Joan B Erland, et al.
Pageof 25